Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Last trade$0.43
Day change-$0.018 (-4.02%)
Day range$0.415 – $0.471
Volume105,459
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for VRAX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for VRAX.
Recent news
Company coverage with links to the original publishers.
Virax Biolabs Group Limited announced positive early pilot data for ViraxImmune™, a blood-based diagnostic test for Long COVID and related post-acute infection syndromes. The test demonstrated 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls across 120+ subjects. The company plans a larger clinical validation study with 300 additional participants, with analysis expected in Q4 2026 and results in Q1 2027, targeting a U.S. Laboratory Developed Test market entry.
Virax Biolabs Group Limited has entered into agreements for a private placement of 12,500,000 ordinary shares and preferred investment options at $0.40 per share, expecting to raise $5 million for working capital and corporate purposes.
Saudi Arabia made its debut at the BIO International Convention 2025, signing over a dozen partnerships, launching a national biotech accelerator program, and establishing the Kingdom as a global hub for life sciences. The Kingdom showcased its ecosystem ready for collaboration across scientific discovery, clinical research, and advanced therapeutics.
Virax Biolabs has extended its exclusive distribution agreement with Cosmos Health to commercialize Mpox Virus Real-Time PCR Detection Kits in the Gulf Cooperation Council countries. The kits have high sensitivity and specificity and can deliver results in under 70 minutes.
Shares of LQR House Inc. (NASDAQ: LQR) rose sharply in pre-market trading. Borg's investor group has acquired a 20% stake in LQR House.
LQR House shares jumped 16.1% to $4.25 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
Rail Vision Ltd. (NASDAQ: RVSN) shares rose 64% to $2.28 in pre-market trading after gaining over 13% on Friday.
Phunware, Inc. (NASDAQ: PHUN) shares jumped 34.5% to $0.1021 in pre-market trading.
MorphoSys AG (NASDAQ: MOR) gained 18.8% to $10.21 in pre-market trading.
Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 13.6% to $1.17 in pre-market trading after falling more than 6% on Friday.
U Power Limited (NASDAQ: UCAR) shares gained 12.7% to $0.1459 in pre-market trading.
WISeKey International Holding AG (NASDAQ: WKEY) gained 11.8% to $2.87 in pre-market trading. SEALSQ launched SEALCOIN.AI in partnership with Google Cloud.
Agenus Inc. (NASDAQ: ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.